Jefferies Financial Group Boosts Centessa Pharmaceuticals (NASDAQ:CNTA) Price Target to $19.00

Centessa Pharmaceuticals (NASDAQ:CNTA) had its target price lifted by Jefferies Financial Group from $13.00 to $19.00 in a research report sent to investors on Wednesday morning, Benzinga reports. Jefferies Financial Group currently has a buy rating on the stock.

Several other research analysts also recently weighed in on CNTA. Oppenheimer reiterated an outperform rating and set a $14.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. Morgan Stanley increased their price target on Centessa Pharmaceuticals from $8.00 to $11.00 and gave the stock an equal weight rating in a research note on Friday, June 21st. Finally, BMO Capital Markets increased their price target on Centessa Pharmaceuticals from $15.00 to $20.00 and gave the stock an outperform rating in a research note on Monday, September 9th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average target price of $17.60.

Centessa Pharmaceuticals Trading Up 12.5 %

Shares of Centessa Pharmaceuticals stock opened at $16.99 on Wednesday. Centessa Pharmaceuticals has a 1 year low of $5.15 and a 1 year high of $17.59. The firm has a market cap of $1.93 billion, a PE ratio of -11.96 and a beta of 1.44. The stock has a fifty day moving average price of $11.76 and a 200-day moving average price of $10.49. The company has a debt-to-equity ratio of 0.27, a current ratio of 13.29 and a quick ratio of 13.29.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Equities research analysts anticipate that Centessa Pharmaceuticals will post -1.61 EPS for the current year.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 12,198 shares of the firm’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $12.17, for a total value of $148,449.66. Following the completion of the transaction, the insider now owns 241,171 shares in the company, valued at approximately $2,935,051.07. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 12,198 shares of the firm’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $12.17, for a total value of $148,449.66. Following the sale, the insider now owns 241,171 shares of the company’s stock, valued at approximately $2,935,051.07. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Saurabh Saha sold 4,169 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $12.32, for a total value of $51,362.08. Following the completion of the sale, the chief executive officer now directly owns 827,755 shares in the company, valued at approximately $10,197,941.60. The disclosure for this sale can be found here. Insiders sold a total of 216,873 shares of company stock worth $3,472,000 in the last quarter. 11.59% of the stock is owned by company insiders.

Institutional Trading of Centessa Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of CNTA. Jump Financial LLC purchased a new position in shares of Centessa Pharmaceuticals during the 4th quarter valued at about $114,000. Trexquant Investment LP purchased a new position in shares of Centessa Pharmaceuticals during the 4th quarter valued at about $114,000. Franklin Resources Inc. raised its holdings in shares of Centessa Pharmaceuticals by 34.1% during the 4th quarter. Franklin Resources Inc. now owns 1,115,817 shares of the company’s stock valued at $8,882,000 after buying an additional 283,469 shares in the last quarter. Platinum Investment Management Ltd. raised its holdings in shares of Centessa Pharmaceuticals by 12.9% during the 4th quarter. Platinum Investment Management Ltd. now owns 381,083 shares of the company’s stock valued at $3,033,000 after buying an additional 43,539 shares in the last quarter. Finally, Octagon Capital Advisors LP raised its holdings in shares of Centessa Pharmaceuticals by 333.2% during the 4th quarter. Octagon Capital Advisors LP now owns 2,060,100 shares of the company’s stock valued at $16,398,000 after buying an additional 1,584,500 shares in the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.